Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6 clinical trials
Also written INT230-6.
How each study uses Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- INT230-6
- 4
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2021 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Intensity Therapeutics, Inc. (2) · Swiss Cancer Institute (1) · Ottawa Hospital Research Institute (1)
Studies
Open first, then newest update. How each study uses Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)RecruitingPhase 3Intensity Therapeutics, Inc.NCT06263231Written as INT230-6
- Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKKRecruitingPhase 2Swiss Cancer InstituteNCT06358573Written as INT230-6
- A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6CompletedPhase 1/2Intensity Therapeutics, Inc.NCT03058289Written as INT230-6
- INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast CancerStatus unknownPhase 2Ottawa Hospital Research InstituteNCT04781725Written as INT230-6